StockData

RxSight, Inc. (RXST) stock

RXSTNasdaqOphthalmic GoodsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3075% below fair value
$5.01+0.18 (+3.73%)

Close on Nov 18, 2026Market cap $208.38MP/E –Yield –

RxSight free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

RxSight's free cash flow for the twelve months ending Jun 30, 2026 was -$27.17M. For fiscal 2025 it was -$19.34M. The highest annual figure on record is -$19.34M in fiscal 2025.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$19.34M–
FY2024Dec 31, 2024-$22.39M–
FY2023Dec 31, 2023-$46.41M–
FY2022Dec 31, 2022-$61.24M–
FY2021Dec 31, 2021-$46.65M–
FY2020Dec 31, 2020-$37.74M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$11.49M–
Q1 FY2026Mar 31, 2026-$11.65M–
Q4 FY2025Dec 31, 2025-$2.25M–
Q3 FY2025Sep 30, 2025-$1.77M–
Q2 FY2025Jun 30, 2025-$5.91M–
Q1 FY2025Mar 31, 2025-$9.41M–
Q4 FY2024Dec 31, 2024-$5.11M–
Q3 FY2024Sep 30, 2024-$453.00K–
Q2 FY2024Jun 30, 2024-$5.55M–
Q1 FY2024Mar 31, 2024-$11.28M–
Q4 FY2023Dec 31, 2023-$9.89M–
Q3 FY2023Sep 30, 2023-$8.64M–
Q2 FY2023Jun 30, 2023-$9.37M–
Q1 FY2023Mar 31, 2023-$18.51M–
Q4 FY2022Dec 31, 2022-$14.22M–
Q3 FY2022Sep 30, 2022-$15.77M–
Q2 FY2022Jun 30, 2022-$15.90M–
Q1 FY2022Mar 31, 2022-$15.36M–
Q4 FY2021Dec 31, 2021-$9.09M–
Q3 FY2021Sep 30, 2021-$14.01M–
Q2 FY2021Jun 30, 2021-$12.80M–
Q1 FY2021Mar 31, 2021-$10.75M–
Q4 FY2020Dec 31, 2020-$8.77M–
Q3 FY2020Sep 30, 2020-$7.55M–

More RxSight figures

See a number that looks wrong?